The present study compared the acceptability of two methadone formulations (syrup vs tablets) in a sample of 44 patients with Opioid Use Disorder (OUD).
The analyses revealed signifi cant differences in favor of the tablet formulation in six of the seven dimensions investigated.
Notable advantages emerged in terms of taste, ease of transport and storage, maintenance of privacy, reduction of dosing issues, and positive impact on daily life.
Most patients receiving the tablet formulation also reported no difficulties in switching from the liquid formulation, expressing an intention to continue with tablets and to recommend them to other patients.
These results suggest that methadone tablets may improve the patient experience and promote greater treatment adherence, while also reducing the indirect costs for services. Future studies with larger samples and attention to pharmacoeconomics will be needed to confirm these findings and support clinical and organizational choices aimed at personalization and sustainability of treatments.